Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
about
Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitisEmerging therapeutic targets in metastatic progression: A focus on breast cancer.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
P2860
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of metastatic breas ...... dotin (CDX-011, CR011-vcMMAE).
@en
type
label
Management of metastatic breas ...... dotin (CDX-011, CR011-vcMMAE).
@en
prefLabel
Management of metastatic breas ...... dotin (CDX-011, CR011-vcMMAE).
@en
P2860
P1433
P1476
Management of metastatic breas ...... dotin (CDX-011, CR011-vcMMAE).
@en
P2093
Andres Forero
Christos Vaklavas
P2860
P2888
P304
P356
10.1007/S40259-014-0085-2
P577
2014-06-01T00:00:00Z